- Finance
- Watchlists
- My Portfolio
- Crypto
- Yahoo Finance Plus
- News
- Screeners
-
Markets
-
Options: Highest Open up Interest
-
Options: Highest Implied Volatility
-
- Videos
- Personal Finance
- Industries
- Contact Us
-
Southward&P 500
-
Dow 30
-
Nasdaq
-
Russell 2000
-
Crude Oil
-
Aureate
-
Silver
-
EUR/USD
-
10-Yr Bond
-
GBP/USD
-
USD/JPY
-
BTC-USD
-
CMC Crypto 200
-
FTSE 100
-
Nikkei 225
Cancer Monoclonal Antibodies Market: Growth Opportunities led by Amgen Inc. and Astellas Pharma Inc. – Technavio
NEW YORK
,
Nov. 29, 2022
/PRNewswire/ — The
cancer monoclonal antibodies market
report is a comprehensive research that provides in-depth qualitative and quantitative intelligence. Technavio’s analysts estimate a market share growth of
USD 33.10 billion
from 2020 to 2025, at a
CAGR of 8.23%.
Technavio has extensively analyzed
15 major vendors,
including Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc, Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Johnson and Johnson Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., and Sanofi SA. This research report aims to capture and analyze the trends, drivers, and challenges that are evolving in the market.
The report extensively covers thecancer monoclonal antibodies marketplace sectionalisation by blazon (naked monoclonal antibodies and conjugated and bi-specific monoclonal antibodies) and geography (North America,
Europe,
Asia, and the Rest of the World (ROW)).Request a Free Sample Written report
Cancer Monoclonal Antibodies Market – Vendors
The market is characterized largely past global vendors. These vendors are investing in technologies to develop advanced biologic therapeutics, such as monoclonal antibodies, for the treatment of various chronic diseases. The key vendors in the global cancer monoclonal antibodies marketplace are focusing on production approvals, M&A, and product launches to gain a competitive edge in the market.
Production Insights and News
• Amgen Inc.:
The company offers BLINCYTO, which is blinatumomab, a bispecific CD19 directed CD3 T cell engager. It is indicated for the treatment of B cell forerunner astute lymphoblastic leukemia and relapsed or refractory B cell precursor acute lymphoblastic leukemia. The company also offers Vectibix, which is a fully human monoclonal antibody specific to the epidermal growth gene receptor used for the handling of wild blazon RAS metastatic colorectal cancer.
•
Astellas Pharma Inc
– The company, by working jointly with Seattle Genetics, develops and offers the Padcev drug to care for locally advanced or metastatic urothelial cancer.
•
AstraZeneca Plc
– The company offers IMFINZI, which is a human immunoglobulin G1 kappa monoclonal antibody that blocks the interaction of PD Fifty 1 with the PD 1 and CD80 molecules used for the treatment of lung cancer and bladder cancer.
For detailed insights about product offerings and the growth strategies adopted past vendors,
buy the report.
Cancer Monoclonal Antibodies Market – Geographical Landscape
North America
is estimated to business relationship for
55%
of the marketplace’southward growth during the forecast period. The cancer monoclonal antibodies market in
North America
is mostly centered in the US. The market in this region will expand more slowly than markets in
Europe
and
Asia. Over the form of the projection period, the expansion of the North American marketplace for cancer monoclonal antibodies will exist supported by the increased incidence of various types of cancer.
Cancer Monoclonal Antibodies Market – MarketSegmentation
The naked monoclonal antibodies segment is estimated to contribute the highest market share to the global market’southward growth during the forecast period. Naked monoclonal antibodies are the most commonly used monoclonal antibodies. They are also known as targeted therapies. The naked monoclonal antibodies segment is expected to grow at a faster pace than other segments during the forecast period. The rapid growth of biotechnology has driven the use of naked monoclonal antibodies for cancer treatment. During the forecast menstruation, new naked monoclonal antibodies, which are currently in clinical trials, are expected to receive approval. These factors will further drive market growth.
Download a free sample study
What are the key data covered in this cancer monoclonal antibodies market report?
-
CAGR of the market place during the forecast catamenia
-
Detailed data on factors that will drive the growth of the cancer monoclonal antibodies market place between 2021 and 2025
-
Precise interpretation of the size of the cancer monoclonal antibodies marketplace size and its contribution to the parent market
-
Authentic predictions nearly upcoming trends and changes in consumer behavior
-
Growth of the cancer monoclonal antibodies market across
North America,
Europe,
Asia, and ROW -
Thorough analysis of the market’s competitive mural and detailed information near vendors
-
Comprehensive analysis of factors that will challenge the growth of cancer monoclonal antibodies market place vendors
Technavio’s library includes over 17,000+ reports, covering more than two,000 emerging technologies.
Subscribe to our “Basic Plan” at just
USD 5,000
and become lifetime admission to Technavio Insights
Related Reports:
Non-melanoma Skin Cancer Market
by Type and Geography – Forecast and Analysis 2022-2026:
The not-melanoma skin cancer market size is projected to grow by
USD 180.97 million
from 2021 to 2026, and the market place’s growth momentum will accelerate at a CAGR of 5.76%.
Anaplastic Thyroid Cancer Drugs Market
by Product and Geography – Forecast and Analysis 2022-2026: The anaplastic thyroid cancer drugs market size is projected to grow by
USD 230.53 one thousand thousand
from 2021 to 2026, and the marketplace’south growth momentum will accelerate at a CAGR of 5.44%.
|
|
|
|
Page number |
120 |
Base of operations yr |
2020 |
Forecast period |
2021-2025 |
Growth momentum & CAGR |
Accelerate at a CAGR of 8.23% |
Market growth 2021-2025 |
USD 33.ten billion |
Market place construction |
Fragmented |
YoY growth (%) |
8.01 |
Regional analysis |
North America, Europe, Asia, and Residual of World (ROW) |
Performing marketplace contribution |
North America at 55% |
Key consumer countries |
U.s., Japan, Germany, France, and UK |
Competitive landscape |
Leading companies, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Companies profiled |
Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc, Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Johnson and Johnson Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., and Sanofi SA |
Market Dynamics |
Parent Market Analysis; Market growth inducers and obstacles; Fast-growing and wearisome-growing segment assay for the forecast period. |
Customization purview |
If our written report has non included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Browse for Technavio “
Health Care
” Research Reports
Table of Contents
1 Executive Summary
ii Market Landscape
-
2.ane Market place ecosystem
-
2.2 Value chain analysis
3 Market Sizing
-
three.1 Marketplace definition
-
three.2 Marketplace segment assay
-
3.3 Market size 2020
-
iii.iv Market outlook: Forecast for 2020 – 2025
four Five Forces Analysis
-
iv.1 5 forces summary
-
four.2 Bargaining power of buyers
-
iv.3 Bargaining power of suppliers
-
4.4 Threat of new entrants
-
4.5 Threat of substitutes
-
iv.6 Threat of rivalry
-
four.seven Market place condition
5 Market Segmentation by Type
-
five.1 Market segments
-
5.2 Comparison by Type
-
5.3 Naked monoclonal antibodies – Market size and forecast 2020-2025
-
5.4 Conjugated and bi-specific monoclonal antibodies – Market size and forecast 2020-2025
-
v.5 Market place opportunity by Type
6 Client landscape
seven Geographic Landscape
-
7.1 Geographic segmentation
-
7.2 Geographic comparing
-
7.three
Due north America
– Market place size and forecast 2020-2025
-
7.4
Europe
– Marketplace size and forecast 2020-2025
-
7.5
Asia
– Market place size and forecast 2020-2025
-
7.6 ROW – Market size and forecast 2020-2025
-
7.7 Fundamental leading countries
-
7.eight Market place opportunity past geography
viii Drivers, Challenges, and Trends
-
eight.1 Market drivers
-
8.2 Market challenges
-
viii.3 Market trends
ix Vendor Mural
-
9.i Vendor landscape
-
9.2 Landscape disruption
-
9.three Competitive scenario
ten Vendor Assay
-
10.1 Vendors covered
-
10.ii Marketplace positioning of vendors
-
10.3 Amgen Inc.
-
10.4 Astellas Pharma Inc.
-
10.five AstraZeneca Plc
-
10.6 Bristol Myers Squibb Co.
-
10.7 F. Hoffmann La Roche Ltd.
-
ten.8 Johnson and Johnson Inc.
-
ten.9 Merck and Co. Inc.
-
ten.10 Novartis AG
-
10.eleven Pfizer Inc.
-
ten.12 Sanofi SA
eleven Appendix
-
11.1 Scope of the report
-
11.2 Currency conversion rates for US$
-
11.3 Research methodology
-
11.4 Listing of abbreviations
Nigh Technavio
Technavio is a leading global engineering science research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’due south study library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across l countries. Their client base of operations consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing customer base relies on Technavio’due south comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and appraise their competitive positions inside changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email:[email protected]
Website:www.technavio.com/
Newsroom: https://newsroom.technavio.org/news/cancer-monoclonal-antibodiesmarket
View original content to download multimedia:https://world wide web.prnewswire.com/news-releases/cancer-monoclonal-antibodies-market-growth-opportunities-led-past-amgen-inc-and-astellas-pharma-inc—technavio-301687728.html
SOURCE Technavio
Source: https://finance.yahoo.com/news/cancer-monoclonal-antibodies-market-growth-110000104.html